Federal judge overturns part of Insys founder Kapoor's racketeering conviction

Insys founder John Kapoor's sentencing is scheduled for January. (AP)

When Insys founder John Kapoor was found guilty on federal racketeering charges in May, it marked the stiffest conviction yet for an opioid executive at the center of the nation's addiction crisis. Now, a federal judge says prosecutors failed to present enough evidence to support some of those claims—likely lowering Kapoor's sentence.

Prosecutors failed to present evidence showing Kapoor and three former Insys sales executives intended for under-the-tongue fentanyl spray Subsys to be prescribed to patients for nonmedical purposes, U.S. District Judge Allison Burroughs said in an order overturning part of the May conviction. 

That order would vacate the criminal conspiracy portion of Kapoor and the other ex-employees' convictions and likely have a big effect on their sentencing in a Boston courthouse scheduled for January. 

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

The order did not affect the sales fraud charges on which those executives were convicted as part of a long-running scheme to drive up prescriptions of Subsys by underselling the drug's addictive properties and capitalizing on patient titration, or gradual resistance to painkillers over time. 

In her order, Burroughs called the defendants' actions "reprehensible and designed to financially incentivize healthcare practitioners to prescribe Subsys without regard for the best interests of their patients," but not grounds for a criminal conspiracy charge. 

"Overturning the verdicts … is not meant to condone or minimize this behavior, but is simply a reflection of the fact that the Government did not prove the requisite intent on the part of Defendants, that is, an intent that healthcare practitioners prescribed the drug to people that did not need it or in unnecessarily high doses," Burroughs wrote. "The Government could have easily proved bribery, but it elected not to charge bribes or kickbacks and now must live with that decision."

RELATED: Insys founder Kapoor found guilty in landmark opioid bribery lawsuit 

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.